RESUMEN
OBJECTIVE: Little is known about the effect of a multi-drug weight loss strategy in obesity treatment, particularly combining bupropion/naltrexone and glucagon-like peptide 1 (GLP-1) analogue. The purpose of this study was to evaluate if there are any additive effects of prescribing bupropion/naltrexone on top of GLP-1 analogue as weight loss therapy. METHODS: This was a retrospective cohort study of adult patients with a body mass index (BMI) ≥ 30 kg/m2 prescribed GLP-1 analogue therapy at an obesity specialist clinic in Vancouver, Canada. We compared a 6 and 12-month change in total body weight loss (TBWL) for those receiving monotherapy from the initiation of GLP-1 analogue therapy with those receiving combination therapy from the initiation of bupropion/naltrexone added-on therapy. Patients prescribed combination therapy were stratified into responder (loss of ≥ 5% TBWL) and non-responder (TBWL < 5%) subgroups based on initial response to the GLP-1 analogue alone for any amount of time. RESULTS: The mean weight loss among patients prescribed GLP-1 analogue monotherapy at 12 months was 11.42 kg, SD 9.95 (9.6% TBWL). There was no significant difference between these two treatment strategies overall (HR 0.88, 95% CI 0.68 to 1.14, p = 0.35). However, when stratified by response to initial GLP analogue therapy, the addition of bupropion/naltrexone was associated with a statistically significant reduction in weight in both the responder (4.3% TBWL (p < 0.01)) and non-responder groups (4.0% TBWL (p < 0.01)). CONCLUSIONS: GLP-1 analogues are an effective treatment for weight loss, and the addition of bupropion/naltrexone is associated with greater weight loss including in patients who are initially non-responsive to GLP-1 analogues.
Asunto(s)
Bupropión , Quimioterapia Combinada , Naltrexona , Pérdida de Peso , Humanos , Bupropión/uso terapéutico , Estudios Retrospectivos , Naltrexona/uso terapéutico , Naltrexona/análogos & derivados , Pérdida de Peso/efectos de los fármacos , Masculino , Femenino , Persona de Mediana Edad , Adulto , Péptido 1 Similar al Glucagón/análogos & derivados , Péptido 1 Similar al Glucagón/uso terapéutico , Obesidad/tratamiento farmacológico , Resultado del Tratamiento , Combinación de Medicamentos , Fármacos Antiobesidad/uso terapéuticoRESUMEN
Both bariatric surgery and medical modification approaches to weight loss for individuals with obesity have been evaluated for their impacts on sexual health, however, a comparison between these interventions has not been undertaken. A convenience sample of 52 females were recruited from community medical and surgical weight loss clinics to participate; 25 received medical management that consisted of dietary guidance and exercise training, and 27 received bariatric surgery. Participants completed self-report questionnaires before and after treatment that examined sexual functioning, sexual satisfaction, relationship satisfaction, depression, anxiety, and body esteem. Sexual functioning decreased in both groups regardless of weight loss approach, p = .037. Sexual satisfaction increased for both groups, p = .005, with significantly greater improvements seen in the medical management group, p = .038. Measures of sexual desire, arousal, and pain did not change after treatment, and there were no group or time effects on relationship satisfaction, depressive symptoms, or body esteem. Lubrication and orgasm function decreased over time for both groups. These results highlight that sexual satisfaction can improve with either weight loss approach, even when sexual function decreases.
Asunto(s)
Cirugía Bariátrica , Conducta Sexual , Depresión , Femenino , Humanos , Libido , Obesidad/terapia , Encuestas y CuestionariosRESUMEN
BACKGROUND: The optimal population rate of cardiac catheterization is unknown. One potential way to determine it would be to examine whether there is a population rate beyond which the yield of high-risk coronary artery disease (CAD) does not rise. METHODS: Using a detailed clinical registry that captures all patients undergoing cardiac catheterization in Alberta, we determined annual population rates of cardiac catheterization and the corresponding yield of cases of high-risk CAD in each of Alberta's 17 health regions from 1995 to 2002. Least squares linear regression analysis and hierarchical modelling methods were then used to assess the linear relation between catheterization rates and rates of high-risk CAD. RESULTS: The age-adjusted average rate of cardiac catheterization among men ranged from 404.9 to 638.1 per 100,000 population aged over 20 years. Among women, the average rate ranged from 171.8 to 314.0 per 100,000. For both sexes, increased regional rates of catheterization were associated with a linearly increasing yield of high-risk CAD, with no evidence of a plateau in yield when more procedures were performed. One additional case of high-risk CAD was identified for every 2.5 additional cardiac catheterization procedures performed among men, and for every 3.7 additional procedures performed among women. INTERPRETATION: The increasing yield of patients with high-risk CAD associated with increased regional population rates of cardiac catheterization, together with the absence of a plateau in yield, suggests that Alberta's population rates of cardiac catheterization are suboptimal to detect people with high-risk CAD.
Asunto(s)
Cateterismo Cardíaco/estadística & datos numéricos , Enfermedad de la Arteria Coronaria/epidemiología , Enfermedad de la Arteria Coronaria/terapia , Modelos Estadísticos , Sistema de Registros/estadística & datos numéricos , Adulto , Factores de Edad , Anciano , Alberta/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medición de RiesgoRESUMEN
Nucleic acid amplification tests (NAAT) are more sensitive than other methods for the diagnosis of Chlamydia trachomatis (CT) genital infections. Two unique sequential testing strategies that employed two different commercial NAAT methods to detect CT in a population of women with widely varying infection risk were evaluated. Specimens from 504 women aged 15 to 75 years were studied. Two endocervical swabs and a urine sample were collected from each woman. One swab was initially tested using the Access enzyme immunoassay (EIA) (Beckman). An aliquot from the EIA extraction was subsequently amplified using the COBAS AMPLICOR CT assay (PCR) (Roche). The second swab was initially tested using the PACE 2 CT hybridization assay (Gen-Probe). An aliquot was pipetted off prior to performing the PACE 2 assay and also amplified using the AMP-CT assay (TMA) (Gen-Probe). Urine samples were tested for CT using both NAAT methods. True CT infections were defined as any woman that was confirmed to be positive on both NAAT results from endocervical swabs. The results of all other CT assays were compared against this expanded gold standard. 28 women were confirmed to have CT infection giving an overall prevalence of 5.6%; low-risk women had a rate of 1.3% while high-risk women had a rate of 9.8%. NAAT methods have a higher sensitivity for detecting CT cervicitis when swabs are tested compared to urine. The positive predictive value of NAAT is decreased when testing low risk women. Limited automation makes it difficult to test a high volume of samples (i.e., > 100 swabs and/or urines) using either of these NAAT methods and continue to provide same day results. Laboratories performing CT testing must define the female population served so that appropriate diagnostic strategies can be employed.
Asunto(s)
Cuello del Útero/microbiología , Infecciones por Chlamydia/microbiología , Chlamydia trachomatis/aislamiento & purificación , Adolescente , Adulto , Anciano , Canadá/epidemiología , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/epidemiología , Infecciones por Chlamydia/orina , Chlamydia trachomatis/genética , Estudios de Factibilidad , Femenino , Humanos , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Prevalencia , Reproducibilidad de los ResultadosRESUMEN
OBJECTIVE: To determine the clinical reason(s) for screening women with varying degrees of risk for genital Chlamydia trachomatis (CT) in the Calgary region. DESIGN: Women aged 15 to 75 years were enrolled at various patient care locations. Pertinent risk factors for genital CT infection were recorded and a gynecological examination was performed. Two endocervical swabs and a first-void urine sample were collected for CT detection using two different nucleic acid amplification test methods. SETTING: Calgary is an urban region that provides healthcare services to a population of almost one million people. Microbiology services are provided by Calgary Laboratory Services through a centralized regional laboratory service. MAIN RESULTS: 504 women with a mean age of 28.1 +/-SD 8.22 years were enrolled. Two hundred ninety-one women (57.8%) were at high risk for acquiring genital CT infection. Twenty-eight (5.6%) tested positive for CT infection and almost all of these women (26 of 28, 93%) had risk factors for acquiring infection. Of the high-risk women, 9.8% were CT positive versus only 1.3% of women at low risk (P=0.0001). Only two of 152 (1.3%) women older than 30 years had genital CT infections. Although most women were asymptomatic, those with laboratory-confirmed CT infection were more likely to have genitourinary symptoms. Three hundred forty-three of 476 (72%) women who did not have genital CT infection had no risk factors, and screening was done as part of a routine gynecological examination for other purposes (prenatal visit, Pap smear). CONCLUSION: Women without risk factors are being screened routinely for genital CT infection as part of a routine gynecological examination done for other reasons. Elimination of the routine screening of low-risk women older than 30 years of age would decrease the current regional utilization of CT tests by as much as one-third.